-
9278 Shared Decistion Making IRL
-
A History of Hemophilia Treatment: Non-replacement Therapy to Gene Therapy
-
A New Tool to Assist in Treatment Selection–The World Federation of Hemophilia (WFH) Shared Decision-making (SDM) Tool
-
A Novel Gene Editing Lexicon Strategy for the Haemophilia Community
-
Durable efficacy and safety in responders: 5-Year post hoc end-of-study analysis of etranacogene dezaparvovec in the phase 3 HOPE-B trial
-
Elucidating the Mechanism Behind the AAV-Derived Factor VIII Assay Discrepancy
-
Gene Therapy as a Global Solution
-
Gene Therapy for Hemophilia A and B Compared to Available Treatments
-
Gene Therapy for Treatment of Hemophilia: An Introduction to Adeno-Associated Viral Vector Gene Transfer
-
Gene Therapy Implementation - A Conversation with Dr. Lishel Horn
-
Gene Therapy in Hemophilia Ongoing and Future Research and What to Expect
-
Gene Therapy in Hemophilia: An APSTH ISTH Sponsored Symposium
-
Getting to Know Gene Therapy: Terminology and Concepts
-
Hemophilia Gene Therapy: Expectations for Reliability and Accessibility
-
Histopathological characterization of immune-mediated hepatocellular injury following gene therapy in hemophilia
-
History of EAHAD and the Upcoming Congress
-
Importance of Monitoring Individuals With Hemophilia for Safety and Efficacy in the Short Term and Long Term
-
ISTH Gene Therapy for Hemophilia Initiative and the Role of EAHAD
-
Latest Clinical Trial Updates for Hemophilia B Gene Therapy
-
Patient Perspectives for Hemophilia in Gene Therapy